RS BioTherapeutics Announces Research Collaboration with University of Colorado School of Medicine
09 July 2024 - 12:00AM
RS BioTherapeutics, whose mission is to develop life-changing
medicines for the millions of people suffering from deadly lung
diseases characterized by pulmonary inflammation, is pleased to
announce a collaboration agreement with the University of Colorado
School of Medicine to evaluate use of its first-in-class,
steroid-free therapeutic platform in the treatment of deadly lung
diseases as well as a chemical countermeasure.
RS BioTherapeutics is collaborating specifically with the lab of
Dr. Tom Hu, an Associate Professor in the Division of Pulmonary and
Sleep Medicine and Associate Director for the Center for Advanced
Drug Development, Department of Pediatrics, at the University of
Colorado School of Medicine. The University of Colorado School of
Medicine is home to numerous seminal discoveries in pulmonary and
critical care medicine, including advances in tuberculosis,
interstitial lung disease, airway disease, cancer, pulmonary
vascular disease, and critical care.
Commenting on the collaboration, RS BioTherapeutics’ Chief
Medical Officer, Dr. Michelle L. Shuffett said, “We are very
pleased to have established this collaboration with Dr. Hu’s lab
and the University of Colorado School of Medicine to evaluate
RSBT-001, our first-in-class, steroid-free therapeutic platform for
deadly lung diseases characterized by pulmonary inflammation and as
a chemical countermeasure for terrorist activities. Dr. Hu’s
academic credentials coupled with his extensive experience in both
the private and government sectors, makes him the ideal partner to
help evaluate these important use cases for RSBT-001.”
Dr. Tom Hu said, “RSBT-001 is currently in development for
Chronic Obstructive Pulmonary Disease (COPD), the third leading
cause of death in the world as well as Idiopathic Pulmonary
Fibrosis (IPF), a rare disease with no cure and a 3-5 year survival
rate. In addition, the anti-inflammatory properties of RSBT-001
demonstrated in preclinical trials underscore its potential to be
an effective chemical countermeasure. I am very excited to
collaborate with Dr. Shuffett and the rest of the RS
BioTherapeutics team to evaluate and advance the development of
RSBT-001.”
Dr. Hu joined the University of Colorado in 2023 after 14 years
of federal services as a Project Officer in the Division of
Chemical, Biological, Radiological, and Nuclear (CBRN)
Countermeasures at the Biomedical Advancement Research and
Development Authority (BARDA), U.S. Department of Health and Human
Services (HHS).
Dr. Hu received a bachelor’s degree in chemistry, Magna Cum
Laude, with an emphasis in Biology from the University of
Pittsburgh in 1996. Dr. Hu went on to earn his M.S. and Ph.D. in
Chemistry from Carnegie Mellon University in 1999 and 2001,
respectively. Following his doctoral work, Dr. Hu moved to the
National Institutes of Health as an Intramural Research Training
Award (IRTA) Fellow. He subsequently went on to GlaxoSmithKline PLC
as a Principal Scientist. During this period, he also completed an
MBA at Villanova University. Dr. Hu then established the Small
Animal Imaging Program at the Medical College of Georgia. During
his most recent position as a Project Officer for the past 14+
years, Dr. Hu was responsible for oversight of technical progress
for the Division of Chemical, Biological, Radiological, and Nuclear
(CBRN) Countermeasures. He has managed more than 20+ company
contracts for the Federal Government, developing medical
countermeasures in the Chemical, Radiological/Nuclear,
Biodosimetry, and Thermal Burn areas, where total contractual
values total over $186+ million. Currently, he serves as an
associate editor and ad hoc reviewer for more than 20 peer-reviewed
journals, has published 29 peer-reviewed articles and made
presentations at over 60 national and international conference
presentations. Dr. Hu has 5 U.S. patents and has been certified as
a Diplomate by the American Board of Medical Physics in Magnetic
Resonance Imaging Physics.
About RS BioTherapeuticsThe mission of RS
BioTherapeutics is to develop life-changing medicines for the
millions of people suffering from deadly lung diseases
characterized by pulmonary inflammation. RS BioTherapeutics is
developing a first-in-class, steroid-free, multi-targeted immune
modulator (RSBT-001) with Chronic Obstructive Pulmonary Disease
(COPD) and Idiopathic Pulmonary Fibrosis (IPF) targeted as first
indications. RS BioTherapeutics owns the exclusive, global license
for RSBT-001 and is projecting filing an Investigational New Drug
Application for RSBT-001 and initiating human trials in 2026. More
information on RS BioTherapeutics can be found at
www.rsbiotherapeutics.com.
Media Contact: David Gutierrez, Dresner
Corporate Services for RS BioTherapeutics, (312) 780-7204,
dgutierrez@dresnerco.com